2-Ethyl-5-oxa-2-azaspiro[3.4]octane

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧唑烯
• 英文名称: 2-Ethyl-5-oxa-2-azaspiro[3.4]octane
• 英文别名: 2-ethyl-5-oxa-2-azaspiro[3.4]octane
• 化学式: C₈H₁₅NO
• 分子量: 141.21
• InChiKey: GUAWIXGXUYXMMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• NLRP3 MODULATORS
  申请人：Innate Tumor Immunity, Inc.

  公开号：US20210308123A1

  公开（公告）日：2021-10-07

  The present invention provides compounds of Formula (I): wherein all of the variables are as defined herein. These compounds are modulators of NLRP3, which may be used as medicaments for the treatment of proliferative disorders, such as cancer in a subject (e.g., a human).
• THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER
  申请人：The Board of Regents of the University of Texas System

  公开号：US20220024891A1

  公开（公告）日：2022-01-27

  The present disclosure reports an extensive medicinal chemistry evaluation of a large collection of Truncating APC-Selective Inhibitor (TASIN) compounds. The compounds were evaluated for activity against a series of colon cancer cell lines with and without truncating APC-mutations, as well as in an isogenic cell line pair reporting on the status of APC-dependent selectivity. A number of very potent and selective compounds were identified, including compounds with good metabolic stability and PK properties. The small molecules reported herein thus represent a first-in-class genotype-selective series that specifically target ape mutations present in the vast majority of CRC patients, and therefore serves as a translational platform towards a potential targeted therapy for colon cancer.
• [EN] THERAPEUTIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS THÉRAPEUTIQUES ET LEURS UTILISATIONS
  申请人：KALA PHARMACEUTICALS INC

  公开号：WO2014130612A1

  公开（公告）日：2014-08-28

  Described herein are compounds of Formula (I)-(III), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of Formula (I)-(III) and pharmaceutical compositions thereof that are mucus penetrating. Methods of using the compounds or pharmaceutical compositions thereof for treating and/or preventing diseases are also provided.
• [EN] HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS<br/>[FR] DÉRIVÉS DE CARBOXAMIDE HÉTÉROAROMATIQUES EN TANT QU'INHIBITEURS DE LA KALLICRÉINE PLASMATIQUE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2020035540A1

  公开（公告）日：2020-02-20

  Heteroaromatic carboxamides of formula (I), wherein Y, R, and X are as defined in the description and the claims, and pharmaceutically acceptable salts thereof can be used in methods for the treatment of diseases which can be influenced by inhibition of plasma kallikrein.